Trial Profile
A Phase 1 Dose-Escalation Study of SCH 900776 as Monotherapy and in Combination With Gemcitabine in Subjects With Advanced Solid Tumors or Lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; MK 8776 (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merck Sharp & Dohme Corp.
- 22 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Apr 2011 Planned End Date changed from 1 Mar 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
- 31 Mar 2011 Planned End Date changed from 1 Oct 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.